3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
4
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
Cyclophosphamide
5
Rituximab
4
Vincristine
3
Prednisone
3
Doxorubicin
3
Etoposide
2
venetoclax
1
pembrolizumab
1
liposomal doxorubicin
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
acalabrutinib
1
Zidovudine
1
Whole-Body Irradiation
1
Valganciclovir
1
Tacrolimus
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Interferon-alpha
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
CLR1404
1
CA-4948
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
pertuzumab
×
90 days
×
Clear all
No trials found.